P. CASTROGIOVANNI, A. DI MURO, A. GORACCI, L. GUIDELLI, M. MARTINUCCI - Vol. 9, September 2003, Issue 3
Testo Bibliografia Summary Indice
Possibile coinvolgimento del sistema oppioide nel disturbo
ossessivo-compulsivo e relative considerazioni psicopatologiche
Possible involvement of opioid systems in obsessive-compulsive disorder:
psychopathological considerations
1 Friedman I, Dar R, Shilony E. Compulsivity and obsessionality in opioid addiction. J Nerv Ment Dis 2000;188:155-62.
2 Maruta NA. The role and place of central mediators and peptide bioregulators in the pathogenesis of emotional disorder in neurotic patients. Lik Sprava 1998;7:82-5.
3 Pitman RK, Van der Kolk BA, Orr SP, Greenberg MS. Naloxone-reversible analgesic response to comabat-related stimuli in PTSD. A pilot study. Arch Gen Psychiatry 1990;47:541-4.
4 Glover H, Lader W, Walker-O’Keefe J, Goodnick P. Numbing scale scores in female paychiatric inpatients diagnosed with self-injurious behavior, dissociative identity disorder, and major depression. Pychiar Res 1997;70:115-23.
5 Diaz-Marsa M, Molina R, Lozano MC, Carrasco JL. Biological basis of posttraumatic stress disorder. Actas Esp Psiquiatr 2000;28:379-84.
6 Friedman MJ. What might the psychobiology of posttraumatic stress disorder teach us about future approaches to pharmacotherapy? J Clin Psychiatry 2000;61(Suppl 7):44-51.
7 Saxe G, Stoddard F, Courtney D, Cunningham K, Chawla N, Sheridan R, et al. Relationship between acute morphine and the course of PTSD in children with burns. J Am Acad Child Adolesc Psychiatry 2000;40:915-21.
8 Baker DG, West SA, Orth DN, Hill HH, Nicholson WE, Ekhator NN, et al. Cerebrospinal fluid and plasma beta-endorphin in combat veterans with PTSD. Psychoneuroendocrinology 1997;22:517-29.
9 Sabioncello A, Kocijan-Hercigonja D, Rabatic S, Tomasic J, Jeren T, Matijevic L, et al. Immune, endocrine, and psychological responses in civilian displaced by war. Psychosom Med 2000;62:502-8.
10 Maremmani I, Marini G, Fornai F. Naltrexone-induced panic attacks. Am J Psychiatry 1998;155:447.
11 Akijama Y, Nishimura M, Suzuki A, Yamamoto M. Naloxone increases ventilatory response to hipercapnic hipoxia in healty adult humans. Am Rew Respir Dis 1990;142:301-5.
12 Klein DF. Panic disorder with agoraphobia. Br J Psychiatry 1993;163:835-7.
13 Liebowitz MR, Fyer AJ, Gorman JM, Dillon D, Appleby IL, Levy G, et al. Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry 1984;41:764-70.
14 Gerra G, Zaimivic A, Zambelli U, Timpano M, Reali N, Bernasconi S, et al. Neuroendocrine responses to psychological stress in adolescents with anxiety disorder. Neuropsychobiology 2000;42:82-92.
15 Haber SN, Wolfer D. Basal ganglia peptidergic staining in Tourette syndrome. A follow up study. Adv Neurol 1992;58:145-50.
16 Leckman JF, Riddle MA, Berrettini WH, Anderson GM, Hardin M, Chappel P, et al. Elevated CSF dynorphin A(1-8) in Tourette’s syndrome. Life Sci 1988;43:2015-23.
17 Van Wattum PJ, Anderson GM, Chappel PB, Goodman WK, Riddle MA, Leckman JF. Cerebrospinal fluid dynorphin A(1-8) and beta-endorphin levels in Tourette’s syndrome are unaltered. Biol Psychiatry 1999;45:1527-8.
18 Sandyk R. Naloxone withdrawal exacerbates Tourette syndrome. J Clin Psychopharmacol 1986;19:371-8.
19 Sandyk R. Naloxone abolishes obsessive-compulsive behavior in Tourette’s syndrome. Int J Neurosci 1987;35:93-4.
20 Kurlan R, Mayumdar L, Deeley C, Mundholkar GS, Plumb S, Como PG. A controlled trial of propoxyphene and naltrexone in patients with Tourette’s syndrome. Ann Neurol 1991;30:19-23.
21 Chappel JN. Training of resident and medical students in the diagnosis and treatment of dual diagnosis patients. J Psychoactive Drugs 1993;25:293-300.
22 Sahley TL, Panksepp J. Brain opioids and autism: an updated analysis of possible linkages. J Autism Dev Disord 1987;17:201-16.
23 Gillberg C. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians. Dev Med Child Neurol 1995;37:239-45.
24 Nagamitsu S, Matsuishi T, Kisa T, Komori H, Miyazaki M, Hashimoto T, et al. CSF beta-endorphin in patients with infantile autism. J Autism Dev Disord 1997;27:155-63.
25 Sandman CA, Barron JL, Chicz-DeMet A, DeMet EM. Brief report: plasma beta-endorphin and cortisol levels in autistic patients. J Autism Dev Disord 1991;21:83-7.
26 Leboyer M, Bouvard MP, Recasens C, Philippe A, Guilloud-Bataille M, Bondoux D, et al. Difference between plasma N- and C-terminally directed beta-endorphin immunoreactivity in infantile autism. Am J Psychiatry 1994;151:1797-801.
27 Willemsen-Swinkels SH, Buitelaar JK, Weijnen FG, Thijssen JH, Van Engeland H. Plasma beta-endorphin concentrations in people with learning disability and self-injurious and/or autistic behaviour. Br J Psyc 1996;168:105-9.
28 Deutsch SI. Rationale for the administration of opiate antagonists in treating infantile autism. Am J Ment Defic 1986;90:631-5.
29 Scifo R, Cioni M, Nicolosi A, Batticane N, Tirolo C, Testa N, et al. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone. Ann Ist Super Sanità 1996;32:351-9.
30 Hoebel BG. Neurotransmitters in the control of feeding and its rewards: monoamine, opiates, and brain-gut peptides. In: Stunkard AJ, Steller E, eds. Eating and its disorders. New York: Raven Press 1984:15-38.
31 Du YP, Zhang YP, Wang SC, Shi J, Wu SH. Function and regulation of cholecystokinin octapeptide, beta-endorphin and gastrin in anorexic infantile rats treated with ErBao Granules. World J Gastroenterol 2001;7:275-80.
32 Morley JE, Levine AS, Grace M. Peptide-YY: a potent orexigenic agent. Brain Res 1985;340:200-3.
33 Rosmos DR, Gosnell BA, Morley JE. Effects of Kappa opiate agonist cholescystokinin and bombesin on intake of diets varying in carbohydrate to fat ratio in rats. J Nutr 1987;117:976-85.
34 Pelchat ML. Of human bondage : food craving, obsession, compulsion, and addiction. Physiol Behav 2002;76:347-52.
35 Leibowitz SF. Opioids and food selection. In: Morgan PG, Pankse PP, eds. Handbook of the hypotalamus, vol 3. New York: Marcel Dekker 1982:299-437.
36 Kaye WH, Pickar D, Naber D, Ebert MH. Cerebral spinal fluid opioid activity in anorexia nervosa. Am J Psychiatry 1982;139:643-5.
37 Kaye WH, Gwirtsman HE, George DT. Elevated cerebral spinal fluid levels of immunoreactive corticotropin-releasing hormones in anorexia nervosa: relation to state of nutrion adrenal function, and intensity of depression. J Clin Endocrinol Metab 1987;64:203-8.
38 Brambilla F, Cavagnini F, Invitti C, Poterzio F, Lampertico M, Sali L, et al. Neuroendocrine and psychopathological measures in anorexia nervosa: resemblances to primary affective disorders. Psychiatry Res 1985;16:165-76.
39 Baranowska B, Radzikowska M, Wasilewska-Dziubinska E, Roguski K, Borowiec M. Disturbed release of gastrointestinal peptides in anorexia nervosa and in obesity. Diabetes Obes Metab 2000;2:99-103.
40 Kim SW. Opioid antagonist in the treatment of impulse-control disorders. J Clin Psyc 1998;59:159-64.
41 Carrion VG. Naltrexone for the treatment of trichotillomania: a case report. J Clin Psychopharmacol 1995;15:444-5.
42 Dannon PN. Topiramate for the treatment of kleptomania: a case series and review of the literature. Clin Neuropharmacol 2003;26:1-4.
43 Brambilla F. Aetiopathogenesis and pathophysiology of bulimia nervosa: biological bases and implications for treatment. CNS Drugs 2001;15:119-36.
44 Brewerton TD, Lydiard RB, Laraia MT, Shook JE, Ballenger JC. CSF beta-endorphins and dynorphin in bulimia nervosa. Am J Psychiatry 1992;149:1086-90.
45 Waller DS, Kiser RS, Hardy BW, Fuchs I, Feigenbaum LP, Uauy R. Eating behavior and plasma beta-endorphin in bulimia. Am Clin Nutr 1989;44:20-3.
46 Fullerton DT, Swift WJ, Getto CJ, Carlson IH. Plasma immunoreactive beta-endorphin in bulimics. Psychol Med 1986;16:59-63.
47 Fullerton DT, Getto CJ, Swift WJ, Carlson IH. Sugar, opioids and binge eating. Brain Res Bull 1985;14:673-80.
48 Mitchell JE, Laine DE, Morley JE. Naloxone but not CCK-8 may attenuate binge eating in patients with bulimia syndrome. Biol Psychiatry 1986;21:1399-406.
49 Mitchell JE, Christenson G, Jennings J, Huber M, Thomas B, Pomeroy C, et al. A placebo-controlled, double-blind crossover study of naltrexone hydrocloride in outpatients with normal-weight bulimia. J Clin Pharmacol 1989;9:94-97.
50 Kiefer F, Horntrich M, Jahn H, Wiedemann K. Is withdrawal-induced anxiety in alcoholism based on beta-endorphin deficiency? Psychopharmacology 2002;162:433-7.
51 Mangold DL, Peyrot M, Giggery P, Wand GS. Endogenous opioid activity is associated with obsessive-compulsive symptomatology in individuals with a family history of alcoholism. Neuropsychopharmacology 2000;22:595-607.
52 Swedo SE, Leonard HL, Kruesi MJ, Rettew DC, Listwak SJ, Berrettini W, et al. Cerebrospinal fluid neurochemistry in children and adolescents with obsessive-compulsive disorder. Arch Gen Psychiatry 1992;49:29-36.
53 Marazziti D, Rossi A, Palego L, Barsanti A, Carrai M, Giannaccini G, et al. Effect of aging and sex on the 3H-paroxetine binding to human platelets. J Affective Disord 1998;50:11-5.
54 Castilla-Cortazar I, Castilla A, Gurpegni M. Opioid peptides and immunodysfunction in patients with major depression and anxiety disorders. J Physiol Biochem 1998;54:203-15.
55 Mavissakalian MR, Jones B, Olson S. Absence of placebo response in obsessive-compulsive disorder. J Nerv Ment Dis 1990;178:268-70.
56 Kaplan HI, Sadock BJ, Grebb JA. Terapie biologiche. In: Kaplan HI, Sadock BJ, Grebb JA, eds. Psichiatria. Manuale di scienze del comportamento e psichiatria clinica. Baltimore: Williams & Wilkins 1997:865-1015.
57 McDougle CJ, Barr LC, Goodman WK, Price LH. Possible role of neuropeptides in OCD. Psychoneuroendocrinology 1999;24:1-24.
58 Nurnberg HG, Keith SJ, Paxton DM. Consideration of the relevance of ethological animal models for human repetitive behavioral spectrum disorders. Biol Psychiatry 1997;15:226-9.
59 Weizman R, Gil-Ad I, Munitz H, Laron Z. Immunoreactive beta-endorphin, cortisol and growth hormone plasma levels in obsessive-compulsive disorder. Clin Neuropharmacol 1990;13:297-302.
60 O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek. Naltrexone decreases craving and alcohol self-administration in alcohl-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psichophrmacol 2002;164:239-40.
61 Keuler DJ, Altemus M, Michelson D, Greenberg B, Murphy DL. Behavioral effects of naloxone infusion in obsessive-compulsive disorder. Biol Psychiatry 1996;40:154-6.
62 Insel TR, Pickar D. Naloxone administration in obsessive-compulsive disorder: report of two cases. Am Journ Psychiat 1983;140:1219-20.
63 Reus VI, Rawitscher L. Possible interaction of Tramadol and antidepressant. Am J Psychiatry 2000;157:839.
64 Goldsmith TD, Shapira NA, Keck PE. Rapid remission of OCD with tramadol Hydrocloride. Am J Psychiatry 1999;156:660-1.
65 Warneke L. A possible new treatment approach to Obsessive-Compulsive Disorder. Can J Psychiatry 1997;42:667-8.
66 Shapira NA, McConville BJ, Pagnucco ML, Norman AB, Keck PE. Novel use of tramadol Hydrocloride in the treatment of tourettes’s syndrome. J Clin Psych 1997;58:174-5.
67 Terenius L. From opiate pharmacology to opioid peptide physiology. Ups J Sci 2000;105:1-15.
68 McGaugh JL, Introini-Collison IB, Cahill LF, Castellano C, Dalmaz C, Parent MB, et al. Neuromodulatory systems and memory storage: role of the amigdala. Behav Brain Res 1993;58:81-90.
69 Braida D, Gori E, Sala M. Relationship between morphine and etonitazene-induced working memory impairment and analgesia. Peptides 1994;15:1513-56.
70 Jang HK, Owyang VV, Hong JS, Gallagher M. Elevated dynorphin in the hippocampal formation of aged rats: relation to cognitive impairment on a spatial learning task. Proc Natl Acad Sci USA 1989;86:2948-51.
71 Gallagher M, King RA, Young NB. Opiate antagonists improve spatial memory. Science 1983;221:975-6.
72 Gannon RL, Terrian DM. U-50, 488H inhibits dynorphin and glutamate release from guinea pig hippocampal mossy fiber terminals. Brain Res 1991;548:242-7.
73 Collier TJ, Routtenberg A. Selective impairment of declarative memory following stimulation of dentate gyrus granule cells: a naloxone-sensitive effect. Brain Res 1984;310:384-7.
74 Merluzzi TV, Taylor CB, Boltwood M, Gotestam KG. Opioid antagonist impedes exposure. J Consult Clin Psychol 1991;59:425-30.
75 Arntz A, Merckelbach H, de Jong P. Opioid antagonist affects behavioral effects of exposure in vivo. J Consult Clin Psychol 1993;61:865-70.
76 Bell IR, Schwartz GE, Bootzin RR, Hau V, Davis TP. Elevation of plasma beta-endorphin levels of shy elderly in response to novel laboratory experiences. Behav Med 1997;22:168-73.
77 Janet P, Raymond F. Les obsessions et la psychasthenie. Paris: Alcan 1919.